Published in J Biol Chem on January 29, 2015
Growth Hormone Mediates Its Protective Effect in Hepatic Apoptosis through Hnf6. PLoS One (2016) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 8.60
Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (2000) 5.22
Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res (2007) 1.33
Survivin and YM155: how faithful is the liaison? Biochim Biophys Acta (2014) 1.22
YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs (2011) 1.14
Targeted therapy for breast cancer. Am J Pathol (2013) 1.09
Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol (2012) 1.08
YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels. Mol Cancer Ther (2012) 1.07
Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer. FEBS J (2013) 1.03
Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. Biochem Pharmacol (2011) 1.03
Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochem Biophys Res Commun (2012) 1.02
Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol (2012) 1.00
YM155 induces EGFR suppression in pancreatic cancer cells. PLoS One (2012) 0.94
Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat Rev (2011) 0.93
The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. Anticancer Res (2012) 0.92
Targeted therapies in gastroesophageal cancer. Eur J Cancer (2014) 0.91
Targeted therapies for gastric cancer: current status. Drugs (2011) 0.89
Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells. Biol Pharm Bull (2013) 0.87
Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway. J Pharmacol Exp Ther (2013) 0.85
Targeted therapy in advanced colon cancer: the role of new therapies. Ann Oncol (2004) 0.85
Survivin-T34A: molecular mechanism and therapeutic potential. Onco Targets Ther (2010) 0.84